Background
Methods
Results
Patient | Age (yr) at Histoplasmosis Diagnosis, Sex | Rheumatic Disease | Anti-TNFa (duration of Therapy in Months Prior to Histoplasmosis Diagnosis) | Other Pre-histoplasmosis IM (month duration) |
---|---|---|---|---|
1 | 11, F | JIA, Psoriatic |
Adalimumab (0.5)
| MTX (5) |
2 | 17, F | JIA, Poly |
Etanercept (1.3)
| MTX (7), burst steroids (1) |
3 | 18, F | JIA, Psoriatic |
Infliximab (14.1)
| MTX (23) |
4 | 15, F | cSLE | - | MTX (3), HCQ (5), burst steroids (12.8) |
5 | 16, F | JIA, Enthesitis | - | None |
6 | 9, M | JIA, Enthesitis |
Adalimumab (1.3)
| MTX (15) |
7 | 17, F | JIA, Oligo | - | MTX (18) |
8 | 16, M | MCTD | - | MTX (31), HCQ (32), maintenance steroids (30) |
9 | 5, F | JIA, Poly | - | None |
Summary, % or Median (range): | 78 % F | 7 JIA, 1 cSLE, 1 MCTD | 44 % TNFai, 1.3 (0.5–14.1) | 78 % DMARD, 18 (4.6–32) 33 % Steroids, 13 (0.6–30) |
Pt | Known Exposure | Histoplasmosis Type | Histology Staining | Antigen (Serum, Urine) | Category | Days Hospitalized (Intensive care) | Antifungal Therapy | Outcome (months to HC or still antigen +) Itraconazole prophylaxis (months) | Months Follow Up After Histoplasmosis Diagnosis, Clearance |
---|---|---|---|---|---|---|---|---|---|
1 JIA | No | PH | ND | +,+ | Probable | 18 | Amphotericin B Itraconazole | HC at 36.7 Prophylaxis for 19.6 | 80, 43.3 |
2 JIA | No | DH | + BAL | +,+ | Proven | 11 | Amphotericin B Itraconazole | HC at 37.2 Prophylaxis for 5.0 | 89, 51.8 |
3 JIA | No | DH | + pulmonary wedge biopsy | +,+ | Proven | 22, (14, ventilation) | Amphotericin B Itraconazole | HC at 12.7 Prophylaxis for 70.0 | 83, 70.3 |
4 cSLE | No | Uncategorized | ND | -,- | Possible | No | Itraconazole* | HC at 3.7 | 33, 29.3 |
5 JIA | No | PH | ND | -,- | Probable | No | Itraconazole Fluconazole | HC at 2.3 | 28, 25.7 |
6 JIA | Lives on farm | DH | ND | +,+ | Probable | 17 | Amphotericin B Itraconazole | HC at 21.2 Prophylaxis for 27.5 | 67, 45.8 |
7 JIA | Attended Bonfire | DH | ND | +,+ | Probable | 6 | Itraconazole | Asymptomatic Antigen < LOQ at 18.0+ Halted itraconazole 18.0 FHD | 26, NA |
8 MCTD | No | DH | ND | +,+ | Probable | 8 (1**, No ventilation) | Amphotericin B Itraconazole | Asymptomatic Antigen decreasing at 11.0 | 11, NA |
9 JIA | Birds and Bats in attic | PH | + pulmonary wedge biopsy | -,- | Proven | No | Itraconazole | HC at 3.3 | 18, 14.7 |
Summary: Median (range) | 33 % Yes 66 % No | 56 % DH 33 % PD 11 % unnoted | 3 Positive 6 ND | 67 % Antigen + (100 % DH, 33 % PH) | 3 Proven 5 Probable 1 Possible | 67 % for 14 (6–22) 11 % needing ventilation | *89 % Itraconazole 56 % Amphotericin B 11 % Fluconazole | 78 % now HC 12.7 to HC (2.3–37.2) 44 % prophylaxis for 23.6 (5–70) | FHD 33 (11-88.5) HC 29.3 (0-70.3) |
Patient Use of Immunosuppressive Medications Following Histoplasmosis Infection was Necessary
Steroids
Pt | IASI (months after histoplasmosis diagnosis) | Systemic Steroids (months after histoplasmosis diagnosis) | Concomitant Itraconazole? | Description of Adverse Event |
---|---|---|---|---|
1 JIA | 3 (7.2) | Intermittent high/burst (5.0 on) | Yes | Red, puffy face (duration unclear) |
2 JIA | 18 (2.4) | Intermittent high/burst (4.3 on) | Yes | 9 + months of weight gain, cushingoid facies, buffalo hump, protruding abdomen with striae, diabetes, adrenal insufficiency, and probable spinal compression fractures. |
3 JIA | 2 (12.4) and 3 (17.9) | No | Yes | None |
4 cSLE | No | Bursts (0, never halted) | Yes | None |
5 JIA | 1 (1.1) | No | Yes | None |
6 JIA | 1 (18.3) | Systemic (15.0) | Yes | < 1 day of sweating, chills, and flushing (allergic reaction*) |
7 JIA | 2 (9.2) | No | Yes | 2.5 + months of cushingoid facies |
8 MCTD | 3 (7.4) | Maintenance (0, never halted) | Yes | None |
9 JIA | 7 (0.8) | No | Yes | Around 9 months of weight gain, increased appetite, moon facies, and protruding abdomen |
Summary: | 89 % received IASI 8.3 (0.8–18.3) | 56 % received systemic steroids 4.3 (0–15.0) | Yes | 44 % experienced non-allergic adverse reactions to steroids* |
Biologics and DMARDs
Pt | Immunosuppressive Medication Resumption (months following histoplasmosis diagnosis, histoplasmosis status) Months to HC | |||
---|---|---|---|---|
1 JIA | HCQ (10.0, still +), ABA (20.1, still +), Intermittent systemic steroid bursts (5.0 on, still +) Time to HC: 36.7 | |||
2 JIA | MTX (11.2, still +), Leflunomide (61.8, HC for 24.6), Stress/Intermittent steroid bursts (4.3, still +) Time to HC: 37.2 | |||
3 JIA | MTX (22.1, HC for 9.4), ABA (14.2, HC for 1.4), Ustekinumab (46.3, HC for 33.6) Time to HC: 12.7 | |||
4 cSLE | HCQ (0, still +), ABA (14.7, HC for 11.0), Low dose maintenance steroids (0, still +) Time to HC: 3.7 | |||
5 JIA | ABA (4.8, HC for 2.5) Time to HC: 2.3 | |||
6 JIA | HCQ (6.2, still +), MTX (51.2, HC for 30.0), Tocilizumab (21.8, HC for 4.9), Systemic steroids (15.0, HC for 0.6) Time to HC: 21.2 | |||
7 JIA | ABA (25.5, still +) Antigen positive < LOQ at 18+ | |||
8 MCTD | HCQ (0, still +), Low dose stress steroids (0, still +) Antigen positive and decreasing at 11+ | |||
9 JIA | None Time to HC: 3.3 | |||
Summary: | Total patients resuming IM: 8/9 (89), with 6/9 (67 %) DMARD; 6/9 (67 %) biologics; and 5/9 (56 %) systemic steroids | Collective median (range) after diagnosis: DMARDs 3.1 (0-51.2) Biologic 17.4 (4.8–25.5) Corticosteroid 4.3 (0–15.0) | Collective median (range) to IM use from HC: DMARD Still + (Still + to 9.4) Biologic 2 (Still + to 11.0) Corticosteroid all still + | Pt median (range) to HC: 12.7 (2.3–37.2), with 2 still low positives |